<bill session="117" type="h" number="6996" updated="2022-12-29T21:48:14Z">
  <state datetime="2022-03-08">REFERRED</state>
  <status>
    <introduced datetime="2022-03-08"/>
  </status>
  <introduced datetime="2022-03-08"/>
  <titles>
    <title type="display">Accelerating Access for Patients Act of 2022</title>
    <title type="short" as="introduced">Accelerating Access for Patients Act of 2022</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act with respect to the accelerated approval of a product for a serious or life-threatening disease or condition, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="M001159"/>
  <cosponsors/>
  <actions>
    <action datetime="2022-03-08">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-03-08" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2022-03-09">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-10-18T14:42:33Z" status="Introduced in House">Accelerating Access for Patients Act of 2022

This bill modifies requirements relating to accelerated approval of drugs for serious or life-threatening diseases or conditions, including by requiring guidance from the Food and Drug Administration and coordinated plans with product sponsors on appropriate postapproval studies.</summary>
</bill>
